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The authors describe a case of undifferentiated pleomorphic sarcoma of the breast occurring in a 50-year-old
woman who presented with a palpable mass in her right breast. She first noticed the mass one month previously.
Core needle biopsy showed connective tissue including epithelioid and spindle cells. The patient underwent total
mastectomy without axillary lymph node dissection. Based on examination of the excised tumor, the initial
pathologic diagnosis was atypical spindle-shaped and ovoid cells with uncertain malignant potential. Histological
findings with immunomarkers led to the final diagnosis of undifferentiated pleomorphic sarcoma.
This case highlights a rare and interesting variant of primary breast sarcoma and the important role of
immunohistochemistry in defining histological type and differential diagnosis. Hence, undifferentiated pleomorphic
sarcoma has been a diagnosis of exclusion performed through sampling and critical use of ancillary diagnostic
techniques.
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Breast sarcomas are histologically heterogeneous none-
pithelial malignancies that arise from the connective tissue
within the breast [1]. They are relatively uncommon and
represent less than 1% of all primary breast malignancies.
Almost every previous reference to this entity in the
medical literature is in the form of isolated case reports.
In all cases, the patients had been diagnosed clinically as
having breast carcinoma and the correct tissue diagnosis
was established histologically. The prevalence, risk factors
and clinical course of breast sarcomas are less well charac-
terized than breast tumors arising from epithelial tissue.
Herein, we report a case of primary undifferentiated pleo-
morphic sarcoma in a 50-year-old woman; this case high-
lights a rare and interesting variant of primary breast
sarcoma and the diagnostic difficulty that physicians and
pathologists may encounter with it.* Correspondence: giancarlo.balbi@unina2.it
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A 50-year-old woman presented to the Breast Unit of Sant’
Anna and San Sebastiano Hospital of Caserta, Italy, after
becoming aware of a non-tender lump in the median areo-
lar area of her right breast. She first noticed the mass one
month previously. During this period, she did not have
any pain or discharge from the nipple. Further, she had no
family history of malignancy, including breast cancer. She
was in antihypertensive therapy.
She had never undergone any radiation and hormone
replacement therapy. On physical examination, the patient
had a demarcated, mobile, firm and fast-growing mass in
her right breast.
The mass was not tender, approximately 4 cm in dia-
meter, and was detected in the median areolar area of the
right breast. There was no clinical evidence of regional
lymphadenopathy.
Mammography revealed an opaque and ovoid lesion oc-
cupying the median equatorial region of the right breast;
this lesion was 35 mm in diameter, with regular margins,
moderate intensity and homogeneous density; there was
no evidence of defined focus of pathological calcification
(Figure 1). Ultrasonography revealed a bulky, firm, hypoe-
choic lesion, with blurred and irregular margins, richlyd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Opaque and ovoid lesion occupying mediant equatorial region of the right.
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This mass was 45 mm in diameter, and referred to as a het-
eroplastic lesion. There was no evidence of lymphadenopathy.
Ultrasound-guided fine needle aspiration on the lesion
showed epithelioid and spindle cells, which were positive
only to the immunohistochemical staining for vimentin
and so we suspected a mesenchymal lesion.
An ultrasound-guided core needle biopsy performed
subsequently showed connective tissue, including cells
similar to those already present in the needle aspirate and
there were many multinuclear osteoclast-like giant cells.
The immunohistochemical staining confirmed the mesen-
chymal nature of the lesion (positivity for vimentin), but
did not indicate clearly a specific histotype for the actin,
CD34 and S100 protein negativity.
Preoperative examination consisted of a complete blood
count, serum kidney and liver function, thyroid function
test, and tests for the levels of several hormones related to
the development of gynecomastia, including estrogen, tes-
tosterone, prolactin and gonadotrophic hormones as well
as cancer markers (CEA, CA 15–3, CA 125). Ultrasound
(US) of the abdomen failed to document any abnormal-
ities. An isotope bone scan did not reveal any abnormal
uptake. All results were within the normal limits.
The patient underwent total mastectomy without axil-
lary lymph node dissection, awaiting histology.
Macroscopic examination of the specimen, measuring
19 × 15 × 8 cm and including the normal nipple, revealed a
grayish, apparently delimited nodular lesion, measuring 10
cm in diameter, with cystic-necrotic and few hemorrhagic
areas. The lesion was 0.5 cm away from the fascia and 1 cm
away from the skin; furthermore, another grayish nodular
lesion measuring 1.5 cm was in the subcutaneous tissue.Microscopic examination of the sections from the speci-
men showed nodular proliferation of pleomorphic-spindle-
shaped and ovoid cells, with connective tissue septa, mixed
with many multinuclear osteoclast-like giant cells that
did not show, mainly, malignant features (Figures 2a-2b;
Figure 3a, 3b).
Necrotic areas and abnormal mitosis were identified.
Immunohistochemical stainings for Cytokeratin Pan
(Figure 4a), Cytokeratin 7-8-18-19, EMA (epithelial
membrane antigen), S100 protein, SMA (smooth muscle
actin) and CD34 were negative; immunohistochemical
staining for vimentin was positive (Figure 4b). Mitotic
activity was observed with a high proliferation index,
assessed with Ki67. Moreover, in the surrounding paren-
chymal component, there were multiple foci of intra-
ductal carcinoma, evaluated with immunohistochemical
staining for muscle actin and collagen IV. The lesion
was contained within the margins of excision.
The histological and immunohistochemical findings
established the diagnosis of undifferentiated pleomorphic
sarcoma with osteoclast-like giant cells of the breast.
The patient was monitored after the operation and we
did not consider that adjuvant treatment was necessary in
the presence of adequate local control and in the absence
of metastatic spread of the disease. Follow-up mammog-
raphy has been satisfactory to date, and she remained well
without tumor recurrence at 15 months.Discussion and conclusion
Primary breast sarcoma is a rare type of cancer arising
from the mesenchymal tissue of the breast; it accounts for
less than one percent of all breast malignancies [2].
Figure 2 a: Breast tissue: invasive neoplasm adjacent to dilacted duct. (Hematoxylin Eosin 20 x). b: Detail of the neoplastic population
(Hematoxylin Eosin 40 x).
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seen in the breast [3] and, in the previous reports, it con-
sisted of 10.5 to 24% of all primary breast sarcomas [3,4].
Most undifferentiated pleomorphic sarcomas of the
breast affect mainly advanced-aged women (over 64 years
of age), but it has also been described in men [5]. How-
ever, it is very difficult to diagnose mammary undifferenti-
ated pleomorphic sarcoma from the clinical features, such
as those revealed by palpation, mammogram and US ap-
pearance. Concerning ultrasound examination and mam-
mography, there are not specific features to obtain a
differential diagnosis between sarcomas. Neither the
symptoms nor the physical findings suggest the diagnosis.
Immunohistochemistry is essential, primarily, to distin-
guish undifferentiated carcinoma from mesenchymal neo-
plasia and, subsequently, after the exclusion of epithelial
neoplasia, it is necessary to define the histogenesis of the
lesion [6].
Immunohistochemical studies in our case were per-
formed on the tissue block containing proliferating tumoral
cells. The tumoral cells stained intensely for vimentin
(a mesenchimal marker), but no immunoreactivity for the
Cytokeratin Pan (epithelial cells marker), Leukocyte Com-
mon Antigen (lymphoid cells marker), SMA (smooth
muscle actin), Desmin (smooth and streaked muscular cells
marker), S100 (neuronal cells marker), CD34 and bcl-2Figure 3 a: Three multinuclear giant cells surrounded by neoplastic m
nuclear features (Hematoxylin Eosin 40 x).(to identify malignant phylloides tumor), CD99 (synovial
sarcoma marker) was detected.
Imaging methods and macroscopy have revealed well-
circumscribed masses with heterogeneous composition.
Further, they have been identified as pale fibrous and fleshy
areas admixed with zones of (cystic) necrosis, hemorrhage
or myxoid features [7].
Microscopically, lesions exihibit cells showing marked
pleomorphism admixed with bizarre giant cells, spindle
cells and variable foamy cells [8]. A storiform growth
pattern and variable chronic inflammatory cells are also
common [7].
Limited data on undifferentiated pleomophic sarcoma
indicate an aggressive clinical course and high incidence
of recurrence and metastasis. Overall, five-year survival
of patients with undifferentiated pleomophic sarcoma
has been roughly 50% [7]. Axillary dissection has been
generally considered unnecessary for undifferentiated
pleomophic sarcoma of the breast, since these tumors
rarely spread through the lymphatic system [2,9]. There-
fore therapeutic treatment of these tumors is mastec-
tomy without lymphoadenectomy. The literature’s data
show approximately 40% local recurrence and that 60%
of the cases develop distant metastases [10]. The role of
adjuvant chemotherapy and radiation also has been un-
clear [2,9].ononuclear cells (Hematoxylin Eosin 40 x). b: neoplastic cells
Figure 4 a: Immunohistochemical staining for Cytokeratin Pan stains the ductal structure while tumor cells are negative(20 x). b:
Positivity for Vimentin(40 x).
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ectomy of the right breast, not including axillary lymph
node dissection.
In the presence of a partial epithelial differentiation, the
basic requirement for the diagnosis of a primary sarcoma
of the breast is the exclusion of epithelial origin (axillary
lymph node dissection is necessary) but the wide sampling
we performed and the immunohistochemical negativity
for cytokeratins and EMA exclude this diagnosis.
In our patient, we found multiple foci of intraductal car-
cinoma but sarcomatous components were the prevailing
neoplastic element of the lesion, thus subcategorizing the
tumor under the sarcoma type with typical biological be-
havior and therapeutic approach [11].
Differential diagnosis should include metaplastic carcinoma
(sarcomatoid), malignant phyllodes tumor, inflammatory myo-
fibroblastic tumor (IMT), myxofibrosarcoma, stromal sar-
coma, leiomiosarcoma, rhabdomyosarcoma and liposarcoma.
Metaplastic carcinoma is a general term used to indicate
breast tumor, in which the predominant component has a
different feature than epithelial or typical ductal. It is a
rare heterogeneous neoplasm generally characterized by
a mixture of adenocarcinoma with dominant areas of
spindle cells, squamous and other mesenchymal differen-
tiation [12]. There are several variants: 1) Ssarcomatoid
carcinoma characterized by malignant struma of fibrohis-
tiocitoma type (pleomorphic sarcoma-like), chondrosar-
coma, osteosarcoma, rhabdomyosarcoma, angiosarcoma
or a combination of these histotypes. In the stromal com-
ponent, the immunohistochemical strainings show posi-
tivity for vimentin and, variably, for pan-cytocheratin and
cytocheratin 7. 2) Spindle cell carcinoma: epithelial com-
ponent is invasive or intraductal. Spindle cells may not be
represented and so simulate a fibromatosis or a low grade
fibroblastic sarcoma with the presence of copious stromal
collagen. 3) Carcinoma with osteoclastic giant cells enters
into the differential diagnosis with our case, but also in
this variant stromal component shows positivity for epi-
thelial markers. 4) Squamous cell carcinoma: the main
problem is the differentiation with a metastatic squamouscell carcinoma, which requires a careful correlation with
clinical data and medical history, in addition to the im-
munochemistry. In some cases of metaplastic carcinoma,
immunohistochemical staining for cytocheratins may be
negative and so we can add staining with EMA. These
forms of neoplasm usually have a more aggressive beha-
vior than ductal carcinoma.
Malignant phyllode tumors consist of a predominant mes-
enchymal component and a benign epithelial component
[6]. According to stromal features, there are three sub-
groups: benign, borderline and malignant lesions. Malignant
lesions, macroscopically, show infiltrative growth and nec-
rotic and hemorrhagic areas. There is histologically the pre-
dominance of a mesenchimal component rather than an
epithelial, nuclear pleomorphism, high mitotic index and
necrosis. The stromal features could simulate pleomorphic
sarcoma, liposarcoma, chondrosarcoma or, exceptionally,
rhabdomyosarcoma. The diagnosis of malignant forms, in
which giant cells may be present, requires an extended sam-
pling to demonstrating the presence of a ductal involvement.
Immunochemistry usually points out the positivity of stro-
mal cells for CD34 and bcl-2 in 25% of the cases.
IMT is a rare spindle cell neoplasm occurring in the
young, characterized by the presence of many inflamma-
tory elements mixed with mesenchymal cells. Histological
features consist of spindle or polygonal cells, admixed
with fibroblasts and myofibroblasts, plasmacells and lym-
phocytes in various proportions.
An IMT is a low-grade neoplastic lesion showing lack of
atipia, hyperchromasia and abnormal mitotic figures [13].
Immunohistochemistry showed positivity of the spindle
cells for vimentin and, variably, for muscle actin and
smooth muscle actin. The positivity for Cytokeratin AE1/
AE3 and ALK is variable. The tumor can be differentiated
from undifferentiated pleomorphic sarcoma by the absence
of necrosis and of marked nuclear pleomorphism, low mi-
totic index and a different immunohistochemical profile.
Myxofibrosarcoma, previously designated as malignant
myxoid fibrous histiocytoma, is the most common sarcoma
in adults and it commonly occurs in people 60 years old or
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shows a uniform myxoid matrix and few nuclear atypia. In
high grade lesions, the tumor shows pleomorphism with
frequent mitotic figures and large necrosis areas. Immuno-
histochemical staining shows positivity for vimentin and
variably for CD34, and negativity for cytokeratin, S-100
and actin. The neoplasm can be distinguished from undif-
ferentiated pleomorphic sarcoma by the uniform presence
of myxoid degeneration areas [14].
Another malignant lesion to be considered in the differ-
ential diagnosis is the stromal sarcoma that originates from
the stroma of the breast. It is completely devoid of epithelial
components, unlike the phyllodes tumor. Macroscopically
the lesion appears solid, grayish-white and homogeneous
with the presence of necrosis’ foci. Histologically it is char-
acterized by a proliferation of monomorphic spindle cells
but sometimes cytologic atypia and high mitotic activity
with infiltrative growth have been reported. Immunohisto-
chemical staining shows strong vimentin reactivity. Of
note, areas with stromal origin in the breast may be focally
immunoreactivate for CD10.
Immunohistochemistry plays a major role in differentiat-
ing pleomorphic sarcomas from other breast mesenchymal
malignancies: leimiosarcomas, liposarcomas and rhabdo-
myosarcomas. The leiomyosarcomas are very rare: 30
cases have been reported in the literature and the forms of
higher degree may have marked nuclear pleomorphism,
high mitotic index and necrosis. This lesion shows diffuse
positivity for actin and muscle desmin which are absent or
minimal in pleomorphic sarcoma. The primary rhabdo-
myosarcomas are more frequently found in association
with malignant epithelial areas of a metaplastic carcinoma
or undifferentiated lesions of malignant phyllodes tumor.
Cases of pure rhabdomyosarcoma of the breast are ex-
tremely rare (about 20 in the Armed Forces Institute of
Pathology case series), are typical of young women (under
40 years old) and show strong actin and desmin reactivity
but also diffuse positivity to the immunohistochemical
staining for myoglobin and myogenin. The liposarcomas
and pleomorphic liposarcomas are extremely rare. The
second are characterized by proliferation of hypoblasts and
demonstration of immunohistochemical positivity for
MUM1 [15].
Breast sarcoma should also be distinguished from benign
spindle cell lesions, such as myofibroblastoma, nodular fas-
ciitis and fibromatosis [16-18]. The fibromatosis are rare
mesenchymal breast lesions, sometimes caused by previous
breast implants and local recurrence. They are character-
ized by infiltrative growth and by monomorphic spindle
cell proliferation, with a low mitotic index and occasional
presence of eosinophil bodies. Compared with pleomorphic
sarcoma, the fibromatosis show the monomorphic cellular
component and the positivity of immunohistochemical
staining for beta catenin. The nodular fasciitis is clinicallycharacterized by painful injury with a rapid onset and
growth. It appears as a circumscribed nodular lesion and
histologically it has been identified by areas of collagen tis-
sue, foci of mucoid degeneration, hemorrhagic extravasa-
tion, lymphocytes and multinucleated giant cells. The
typical cells are myofibroblasts, with mild nuclear pleo-
morphism and numerous mitoses. Immunohistochemical
evaluation shows positivity for vimentin, actin and CD10.
In our case, the tumor did not arise from the epithelial
tissue but from the mesenchymal tissue of the breast,
being consistent with the negative immunoreactivity for
CK, EMA, SMA, desmin and S-100 proteins.
Histologic findings of many atypical cells and abnormal
mitotic activity, a negative immunoreactivity for SMA and
ALK helped to exclude IMT from the differential diagnos-
tic consideration. This case was distinguished from myofi-
broblastoma by negative immunoreactivity for SMA, CK,
EMA, CD34, desmin and S100 protein.
Instead, osteosarcoma can be classified into three sub-
types, including fibroblastic, osteoblastic and osteoclastic
osteogenic sarcomas. Histological differentiation is impor-
tant, since fibroblastic osteogenic sarcomas are associated
with a better survival outcome than other pathological
types [19,20]. The presence of bone or osteoid elements in
breast lesions is relatively rare, but has also been described
in epithelial neoplasms, such as metaplastic carcinomas.
Metaplastic carcinomas typically are immunoreactive for
cytokeratin, identifying them as epithelial neoplasms [19].
The basic requirements for the diagnosis of a primary
osteosarcoma of the breast, according to Allan and Soule,
include (a) the presence of neoplastic osteoid or bone, (b)
the exclusion of origin in the bone, and (c) the absence of
an epithelial component [21]. In our patient, the result of
an isotope skeletal bone scan aided in excluding the possi-
bility of a primary bone tumor, while histological and
immunohistochemical analyses showed no evidence of epi-
thelial differentiation.
Although histological features of the removed mass
were suggestive of a malignant pleomorphic spindle cell
tumor, the immunohistochemical responses failed to dis-
close the line of tumoral differentiation. Hence, the final
diagnosis of the tumor was undifferentiated pleomorphic
sarcoma.
In conclusion, undifferentiated pleomorphic sarcoma of
the breast is an uncommon mesenchimal neoplasm that
presents diagnostic challenges. Mammography and breast
ultrasonography showed a breast lump, but features were
often not diagnostic.
It has been a diagnosis of exclusion performed
through sampling and critical use of ancillary diagnos-
tic techniques.
Therefore, as with all rare tumors, undifferentiated pleo-
morphic sarcoma should be managed in reference centers
to determine whether treatment of choice is surgical
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adjuvant therapy can have beneficial effects.
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